Of Early Detection During Lung Cancer Articles & Analysis
16 news found
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer ...
Business Update Highlights “Our Q2 results demonstrate BioMark’s continued efforts to advance our technology platform with exceptional clinical data, expand our global partnerships, and accelerating the commercialization of its early lung cancer blood-based assay despite a challenging macro environment” said CEO Rashid Bux. ...
Other companies have developed their own technologies, many of which are aimed at detecting and providing volumetric measurements of pulmonary nodules. “Pulmonary nodules are a big topic, particularly with the advent of chest CT in high-risk patients for the early detection of lung cancer,” Krestin ...
ByFluidda
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
(“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round. The round was led by RA Capital Management, with participation from new investors including funds and accounts managed by BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM. ...
August 1 marks World Lung Cancer Day -- a time to raise awareness of the need for increased lung cancer research and innovation. Anyone can get lung cancer. Here are the facts you need to know: Lung cancer is the leading cause of cancer deaths worldwide More patients die every year from lung cancer than from prostate, breast, and colon cancer combined The lung cancer five-year survival rate ...
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® ...
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its CellCT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. These non-cancerous cells have been affected by the presence of the cancer cells and have undergone ...
VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. The abstract presentation includes a breakthrough research study using the ...
VisionGate, a clinical stage oncology pharmaceutical and diagnosticscompany, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of commercial-capable Cell-CT systems were delivered to VisionGate’s clinical laboratory in Phoenix, Arizona earlier this year, setting the stage for the company’s advancement. “I am pleased ...
Bonnie Addario of The Bonnie J. Addario Lung Cancer Foundation and Dr. David Jablons, Director of the UCSF Thoracic Oncology Program are honored to announce today that Porsche will be a major collaborator in the October 16, 2011 exclusive QUAIL PORSCHE RACE CAR CLASSIC in Carmel, California at the famed Quail Lodge and Golf Club. This once-in-a-lifetime gathering of vintage Porsche race cars from ...
For more than three years, the Bonnie J. Addario Lung Cancer Foundation in San Francisco and the Joan Gaeta Lung Cancer Fund (formerly Foundation) in Atlanta, have worked tirelessly back and forth across the country in their efforts to eradicate lung cancer. ...